Biomea Fusion, Inc.

Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. The company was founded in 2017 with the goal of creating targeted treatments built through expertise in chemistry and a deep understanding of metabolic biology. Following a strategic realignment announced in 2025, the company now operates with a streamlined structure emphasizing capital efficiency, scientific discipline, and focused execution, with approximately 40 employees ⁴⁰.

The core business model revolves around the development of novel small molecule therapies. The company generates revenue through the potential commercialization of these drug candidates, though it has not generated any revenue from product sales to date ²⁶. The primary customer segments, if products are approved, would be patients with type 1 and type 2 diabetes and obesity. The company's approach involves developing covalent small molecule drugs, which are synthetic compounds forming a permanent bond to their target protein, offering potential advantages such as greater target selectivity, lower drug exposure, and more durable responses ⁸⁵.

The company's pipeline is centered on two core drug candidate development programs: icovamenib and BMF-650. Icovamenib is the lead clinical program's drug candidate, an orally bioavailable, selective, covalent inhibitor of menin, currently being developed in two clinical and multiple preclinical studies. It investigates icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity ⁵. Menin is a transcriptional regulator implicated in beta-cell dysfunction, and inhibiting it may allow for the regeneration and restoration of functional beta cells, enhancing insulin synthesis and secretion ⁶. Icovamenib has also shown in preclinical studies to increase GLP-1 receptor expression, potentially improving incretin signaling and responsiveness to incretin-based therapies ⁷. The company is concluding studies exploring icovamenib's potential in oncology and plans to explore partnerships for its oncology assets, such as BMF-500, a covalent inhibitor of FLT3, which is currently in a Phase I study ⁸⁶.

BMF-650 is an investigational, next-generation oral glucagon-like peptide-1 (GLP-1) receptor agonist (RA) in development for the treatment of obesity ⁵. GLP-1 RAs are a class of medications that bind to and activate GLP-1 receptors, mimicking the effects of native GLP-1, and have demonstrated efficacy in improving glycemic control, promoting weight loss, and enhancing insulin sensitivity ¹⁰. BMF-650 has shown positive early preclinical activity, including improved glucose-stimulated insulin secretion, reduction in blood glucose concentration, and appetite suppression in cynomolgus monkeys. Comparative preclinical studies against a leading oral GLP-1 RA indicated higher oral bioavailability and a less variable pharmacokinetic profile for BMF-650 ¹⁰.

For the fiscal year ended December 31, 2025, Biomea Fusion, Inc. reported a net loss of $61.797 million ¹⁰. Total operating expenses were $83.512 million ⁹. Research and development expenses amounted to $61.979 million ¹¹, while general and administrative expenses were $19.328 million ¹². An impairment of long-lived assets of $2.205 million was recorded ¹³. The company also reported a change in fair value of common warrant liability of $19.857 million ¹⁴ and interest and other income, net, of $1.858 million ¹⁵. As of December 31, 2025, the company had cash and cash equivalents of $55.812 million ¹⁶ and restricted cash of $0.369 million ¹⁷, totaling $56.181 million in cash, cash equivalents, and restricted cash. The accumulated deficit stood at $449.0 million ¹⁸. The company had 72,299,440 shares of common stock issued and outstanding ¹⁹.

Comparing the year ended December 31, 2025, to December 31, 2024, the net loss decreased from $138.426 million ²⁰ to $61.797 million ¹⁰. Total operating expenses decreased by $60.558 million ²¹, from $144.070 million ²² in 2024 to $83.512 million ⁹ in 2025. Research and development expenses decreased by $56.106 million ²³, from $118.085 million ²⁴ in 2024 to $61.979 million ¹¹ in 2025, primarily due to a $28.502 million ²⁵ decrease in clinical activities related expenses following the strategic realignment to focus on core assets and ceasing internal oncology development. Manufacturing costs decreased by $4.414 million ²⁶, and preclinical activities related expenses decreased by $5.778 million ²⁷. Personnel-related expenses within R&D decreased by $11.293 million ²⁸ due to a decrease in headcount. General and administrative expenses decreased by $6.657 million ²⁹, from $25.985 million ³⁰ in 2024 to $19.328 million ¹² in 2025, mainly driven by a $5.9 million ³¹ decrease in personnel-related expenses. Interest and other income, net, decreased by $3.786 million ³², from $5.644 million ³³ in 2024 to $1.858 million ¹⁵ in 2025, primarily due to a decrease in cash and cash equivalents balance. An impairment of long-lived assets of $2.205 million ¹³ and a change in fair value of common warrant liability of $19.857 million ¹⁴ were recorded in 2025, with no comparable figures in 2024.

During the fourth quarter of 2025, the company initiated two Phase II clinical studies, COVALENT-211 and COVALENT-212, to evaluate icovamenib in patients with type 2 diabetes ⁹. The COVALENT-121 food-effect study was completed in the fourth quarter of 2025, demonstrating optimal pharmacokinetic exposure and a consistent safety profile for icovamenib when administered within 30 minutes after a meal ⁹. The former clinical hold on COVALENT-112 in type 1 diabetes, imposed in June 2024, was lifted in September 2024 ⁹. In September 2025, BMF-650 received IND-clearance from the FDA, and the Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers is ongoing ⁸⁶. The company also completed an underwritten public offering in June 2025, issuing 19,450,000 shares of common stock at $2.00 per share ³⁴ and pre-funded warrants for up to 550,000 shares at $1.9999 per share ³⁵, along with common warrants for up to 23,000,000 shares at an exercise price of $2.50 per share ³⁶. In July 2025, underwriters partially exercised their over-allotment option for an additional 1,381,262 shares of common stock at $2.00 per share ³⁷. Another underwritten public offering was completed in October 2025, issuing 11,195,121 shares of common stock at $2.05 per share ³⁸ and pre-funded warrants for up to 1,000,000 shares at $2.0499 per share ³⁹, with accompanying common warrants for up to 14,024,389 shares at an exercise price of $2.50 per share ⁴⁰.

Biomea Fusion, Inc. expects to continue incurring significant expenses and operating losses for the foreseeable future, with net losses potentially fluctuating significantly depending on the timing and expenditures of planned research and development activities ⁸⁶. The company does not anticipate generating revenue from product sales unless and until regulatory approval is obtained and a product candidate is commercialized, with no assurance of ever generating significant revenue or profits ⁸⁶. Based on the current operating plan, existing cash and cash equivalents, and restricted cash of $56.2 million ⁴¹ as of December 31, 2025, are only sufficient to fund operations into the first quarter of 2027 ⁴². The company will require substantial additional capital to fund operations, including to conduct and complete clinical trials for any product candidates, and adequate additional funding may not be available on acceptable terms or at all ⁹².

A major growth area for the company is the continued development of icovamenib in type 2 diabetes. The company is prioritizing its development in two key patient populations with significant unmet medical need: severe insulin deficient diabetes patients and patients not achieving glycemic targets on GLP-1 RA-based therapies ¹¹. The severe insulin deficient diabetes population is estimated to include approximately 14 million ⁴³ type 2 diabetes patients across the United States and European Union, and more than 50 million ⁴⁴ patients in Asian countries ¹¹. The company has initiated a Phase II randomized, double-blind, placebo-controlled clinical trial (COVALENT-211) for participants with type 2 diabetes not achieving glycemic targets despite antihyperglycemic medications, and a similar Phase II trial (COVALENT-212) for those not achieving targets despite GLP-1 RA-based therapy ¹¹. The company expects to conduct a readout of the 26-week primary endpoint data for COVALENT-211 and COVALENT-212 in the fourth quarter of 2026 ⁹.

Another significant growth vector is the advancement of BMF-650 within the metabolic pipeline. BMF-650, an investigational next-generation oral GLP-1 RA candidate, is currently being evaluated in a Phase I GLP-131 trial ¹¹. The company expects to announce initial 28-day weight loss clinical data from this trial in the second quarter of 2026 ¹¹. BMF-650's unique pharmacokinetic properties and encouraging preclinical efficacy profile are believed to offer the potential for a differentiated oral GLP-1 RA option for obesity and metabolic disease ¹¹.

Operationally, the company expects its research and development expenses to increase substantially over the next few years as it seeks to initiate and complete clinical trials, pursue regulatory approval of icovamenib, and advance BMF-650 and other programs through preclinical and clinical development ⁸⁷. General and administrative expenses are also anticipated to increase substantially due to staff expansion, additional occupancy costs, and expenses associated with operating as a public company, including compliance with SEC and Nasdaq rules, higher legal and auditing fees, investor relations costs, and insurance premiums ⁸⁸. The company's future intellectual property expenses may also increase as its product portfolio expands ⁸⁸.

The company plans to raise additional capital through public or private equity offerings, debt financings, collaborations, and licensing arrangements or other sources ⁹². As of December 31, 2025, the company had $94.8 million ⁴⁵ available under its 2022 ATM Program ⁹¹. The number of shares available for future grant under the 2021 Plan will automatically increase each year on January 1, from January 1, 2022 to January 1, 2031, by the lesser of (A) five percent of the shares of Common Stock outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the Board or the Committee ⁷². Additionally, shares are reserved for issuance under the ESPP, which will automatically increase each year on January 1, from January 1, 2022 to January 1, 2031, by the lesser of (i) one percent of the shares of Common Stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares as may be determined by the Board, provided no more than 4,500,000 shares ⁴⁶ may be issued under the ESPP ⁷².

Biomea Fusion, Inc. faces substantial risks, including its limited operating history, lack of revenue generation, and significant net losses, with an accumulated deficit of $449.0 million ¹⁸ as of December 31, 2025. The company will require substantial additional capital to finance operations, as its existing cash, cash equivalents, and restricted cash of $56.2 million ⁴¹ are only sufficient to fund operations into the first quarter of 2027 ⁴², raising substantial doubt about its ability to continue as a going concern ³⁰. The company's novel small molecule therapies, particularly covalent binders, are an emerging field with inherent risks of toxicity from off-target interactions if poorly designed ³². Preclinical and clinical drug development is a lengthy, expensive, and uncertain process, with no guarantee that early positive results will be replicated in later-stage trials or that product candidates will achieve regulatory approval ³³. Delays in clinical trials, such as the previous clinical hold on icovamenib INDs from June 2024 to September 2024 ³⁵, can increase costs and shorten patent protection periods ³⁵. The market opportunities for product candidates may be relatively small, initially limited to patients who have failed prior treatments, and estimates of target patient populations may be inaccurate ³⁷. The biotechnology and pharmaceutical industries are intensely competitive, with many competitors possessing significantly greater financial resources and expertise ³⁸. Product candidates may cause significant adverse events or undesirable side effects, potentially preventing regulatory approval, limiting market acceptance, or leading to product liability claims ³⁹. The company relies heavily on third parties for preclinical studies, clinical trials, and manufacturing, exposing it to risks if these third parties fail to perform their contractual duties or meet deadlines ⁵⁶. Dependence on single-source suppliers for ingredients and manufacturing processes creates risks of supply disruptions and price increases ⁵⁸. Geopolitical events, such as trade wars or political unrest in China, could disrupt product development and manufacturing operations, particularly given the company's reliance on third-party manufacturers outside the United States ⁵⁵. Changes in U.S. government policy, such as the 100% tariff on brand-name or patented drugs unless manufacturing expands in the U.S. announced on September 25, 2025 ⁵⁵, and the BIOSECURE ACT effective December 18, 2025, restricting engagement with certain Chinese biotechnology companies ⁵⁵, could materially adversely affect the business. The company is subject to stringent and changing laws relating to privacy, data protection, and information security, including the California Consumer Privacy Act (CCPA) and California Privacy Rights Act of 2020 (CPRA), and new regulations on artificial intelligence, with potential for significant fines and liability for non-compliance ⁵¹. The U.S. Supreme Court's June 2024 decision in Loper Bright Enterprises v. Raimondo, overturning the Chevron doctrine, could lead to increased regulatory uncertainty and legal challenges to agency regulations ⁵².

Management's message to shareholders emphasizes a strategic realignment in 2025 to focus on becoming a clinical-stage diabetes and obesity medicines company, with a streamlined operating structure designed for capital efficiency, scientific discipline, and focused execution ⁵. The company's mission is to deliver transformative treatments that restore metabolic health, with an aim to cure ⁵. Key strategic priorities include executing Phase II development of icovamenib in type 2 diabetes, specifically targeting severe insulin deficient diabetes patients and those not achieving glycemic targets on GLP-1 RA-based therapies ¹¹. Management expects to conduct a readout of the 26-week primary endpoint data for the COVALENT-211 and COVALENT-212 studies in the fourth quarter of 2026 ⁹. Another priority is to conclude the Phase I trial of BMF-650 in obesity and advance it within the metabolic pipeline, with initial Phase I data anticipated in the second quarter of 2026 ¹¹. The company also intends to evaluate opportunities to enhance the potential of its programs through collaborations with third parties, particularly for its oncology assets like BMF-500, while retaining full worldwide development and commercialization rights to its product candidates ¹¹. Management acknowledges the need for substantial additional capital to fund future operations, as existing cash and cash equivalents, and restricted cash of $56.2 million ⁴¹ are only sufficient to fund operations into the first quarter of 2027 ⁴², and there is substantial doubt about the company's ability to continue as a going concern without further financing ³⁰.